ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06182072)
A Phase I/Ib Trial of ProAgio, an Anti- ฮฑvฮฒ3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel or Gemcitabine, Nab-paclitaxel and Atezolizumab for Advanced Pancreatic Cancer
๐ฉบ Plain-English Summary (8th-Grade Level)
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)
Who can join: Review the eligibility criteria below.
Location: O'Neal Comprehensive Cancer Center, University of Alabama โ Birmingham, Alabama
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- O'Neal Comprehensive Cancer Center, University of Alabama โ Birmingham, Alabama
๐ Contact the Study Coordinator
Phone: (615) 614-1185
Email: damon.michaels@medelis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Ductal Adenocarcinoma (PDAC)
- Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial โ Boston, Massachusetts
- Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life โ Vancouver, British Columbia
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) โ Burlington, Vermont
- Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer โ La Jolla, California
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer โ Los Angeles, California
Explore by condition: All Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.